Arbutus Biopharma
ABUS
ABUS
122 hedge funds and large institutions have $154M invested in Arbutus Biopharma in 2021 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
3% more capital invested
Capital invested by funds: $149M → $154M (+$4.95M)
5.95% less ownership
Funds ownership: 35.18% → 29.24% (-5.9%)
Holders
122
Holding in Top 10
1
Calls
$14.4M
Puts
$9.51M
Top Buyers
| 1 | +$7.85M | |
| 2 | +$4.64M | |
| 3 | +$3.5M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.07M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.6M |
Top Sellers
| 1 | -$8.67M | |
| 2 | -$3.84M | |
| 3 | -$2.24M | |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$2.13M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.7M |